Optics
Independent bench evidence supports optical refinement within the established focal concept.
Localized diffractive changes and greater far-intermediate continuity do not establish a new focal architecture.
Review p. 04 · reference 2Evidence Review · 03
Clareon PanOptix Pro
Refining an Established Trifocal
An established trifocal, optically refined. This review separates the manufacturer’s efficiency claims, independent optical metrology and direct clinical evidence to ask how much of the refinement reaches the patient.
Read opens the full PDF in a new tab.
The evidence review in one minute
Three key takeaways
Clinical
Preserved corrected distance performance is better supported than incremental patient benefit.
Two posted randomized contralateral studies met their registered noninferiority criteria. Registry results are not journal peer review.
Review p. 06 · references 3–4Uncertainty
A meaningful dysphotopsia or contrast-sensitivity advantage remains unestablished.
Manufacturer-reported scatter reduction must not be interpreted as an equivalent reduction in halos or glare.
Review pp. 07, 09The central question
How much of an optical refinement ultimately reaches the patient?
The definitive full evidence review
Follow the evidence.
Complete evidence, methods and references are in the PDF.
Read the PDF on this page
If your browser does not display the reader, open the PDF directly.
Publication transparency
These declarations concern OIE and its author. They do not describe the funding or financial relationships of the studies reviewed.
Evidence appraised through 19 September 2026. Later findings may change interpretation.